Company Overview and News

2018-04-19 globenewswire
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018. Management will host a conference call to review the results at 4:30 p.m. ET on the same day.
Upvote
Downvote

2018-04-18 globenewswire
WATERTOWN, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting being held in Honolulu, Hawaii, from April 29 – May 3, 2018.
Upvote
Downvote

2018-03-28 reuters
* PSIVIDA CORP. ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC. AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS, INC.
Upvote
Downvote

2018-03-28 reuters
* PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC
Upvote
Downvote

2018-03-28 globenewswire
Acquisition and additional funding significantly accelerate the company’s transformation to a specialty biopharmaceutical company with the potential to commercialize two ophthalmic products in 1H 2019
Upvote
Downvote

2017-12-14 reuters
* PSIVIDA CORP - BASED ON STUDY FINDINGS, IMPLANT WAS WELL TOLERATED AND SHOWED POTENTIAL ANALGESIC EFFECTS THROUGH SIX-MONTH STUDY PERIOD Source text for Eikon: Further company coverage:
Upvote
Downvote

2017-07-10 sec.gov
EX-99.1 Exhibit 99.1 pSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSividas Revenue Generation WATERTOWN, MA., July 10, 2017 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement wi
Upvote
Downvote

2017-07-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2017 pSivida Corp. (Exact Name of Registrant as Specified in Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote
Downvote

2017-07-10 reuters
* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation
Upvote
Downvote

2017-06-30 sec.gov
EX-99.1 Exhibit 99.1 pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson WATERTOWN, Mass., June 28, 2017 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson, a seasoned healthcare executive has been elected to the Companys Board of Directors.
Upvote
Downvote

2017-06-30 sec.gov
EX-10.1 Exhibit 10.1 pSivida Short Term Incentive Plan Purpose pSividas Short Term Incentive (STI) Plan (the Plan) is designed to drive the achievement of Corporate Performance by providing employees the opportunity to receive discretionary Short Term Incentive Awards at the Compensation Committees discretion, including a variety of compensation vehicles such as Cash Bonuses based on Corporate Performance and Individual Performance each budget/performance year.
Upvote
Downvote

2017-06-30 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2017 pSivida Corp. (Exact Name of Registrant as Specified in Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote
Downvote

2017-06-30 sec.gov
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints John Mercer, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of pSivida Corp.
Upvote
Downvote

2017-06-30 sec.gov
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints John Mercer, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of pSivida Corp.
Upvote
Downvote

2017-06-29 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2017 pSivida Corp. (Exact name of registrant as specified in its charter) Delaware 000-51122 26-2774444 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote
Downvote
Related Articles
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...